Georgetown University Medical Center is a biomedical research and educational organization that responsible for over 80% of Georgetown University's sponsored research funding and is led by Edward B. Healton, MD, the Executive Vice President for Health Sciences and Executive Dean of the School of Medicine.

During the past decade, Georgetown University Medical Center conducted 124 clinical trials. In the 10-year time frame, 124 clinical trials started and 57 clinical trials were completed, i.e. on average, 46% percent of trials that started reached the finish line to date. In the past 5 years, 32 clinical trials started and 28 clinical trials were completed. i.e. 87.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Georgetown University Medical Center" #1 sponsor was "Georgetown University" with 32 trials, followed by "Hoffmann-La Roche" with 27 trials sponsored, "National Institute of Allergy and Infectious Diseases (NIAID)" with 20 trials sponsored, "Pfizer" with 15 trials sponsored and "Glaxo Wellcome" with 15 trials sponsored. Other sponsors include 167 different institutions and companies that sponsored additional 114 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Georgetown University Medical Center" #1 collaborator was "National Cancer Institute (NCI)" with 8 trials as a collaborator, "Bristol-Myers Squibb" with 7 trials as a collaborator, "Pfizer" with 7 trials as a collaborator, "Glaxo Wellcome" with 5 trials as a collaborator and "Eli Lilly and Company" with 3 trials as a collaborator. Other collaborators include 136 different institutions and companies that were collaborators in the rest 118 trials.

According to Clinical.Site data, the most researched conditions in "Georgetown University Medical Center" are "HIV Infections" (56 trials), "Breast Cancer" (15 trials), "Alzheimer Disease" (9 trials), "Alzheimer's Disease" (7 trials) and "Advanced Cancer" (6 trials). Many other conditions were trialed in "Georgetown University Medical Center" in a lesser frequency.

Most popular intervention types in "Georgetown University Medical Center" are "Drug" (220 trials), "Biological" (20 trials), "Other" (14 trials), "Behavioral" (12 trials) and "Device" (10 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (23 trials), "Zidovudine" (16 trials), "Gemcitabine" (9 trials), "Lamivudine" (9 trials) and "Nivolumab" (8 trials). Other intervention names were less common.

The vast majority of trials in "Georgetown University Medical Center" are 255 trials for "All" genders, 12 trials for "Male" genders and 10 trials for "Female" genders.

Currently, there are NaN active trials in "Georgetown University Medical Center". undefined are not yet recruiting, 34 are recruiting, 39 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 153 completed trials in Georgetown University Medical Center, 1 suspended trials, and 36 terminated clinical trials to date.

Out of the total trials that were conducted in Georgetown University Medical Center, 53 "Phase 1" clinical trials were conducted, 97 "Phase 2" clinical trials and 84 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 31 trials that are defined as “Not Applicable".